Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 September 2004 | Volume 141 Issue 5
Background: Heart failure is a common, costly, and debilitating illness. Resynchronization of ventricular contraction in patients with heart failure improves ejection fraction. The long-term morbidity and costs associated with such cardiac resynchronization therapy remain unclear.
Objective: To assess the incremental cost-effectiveness of cardiac resynchronization therapy.
Design: Markov model with Monte Carlo simulation. Future costs and effects were discounted at 3%.
Data Sources: Effects data were obtained from a concurrent systematic review. Health-related quality-of-life and cost data were obtained from publicly available data or from surveys.
Target Population: Patients with reduced ventricular function and prolonged QRS.
Time Horizon: Lifetime.
Perspective: U.S. health care system.
Interventions: Cardiac resynchronization therapy versus medical therapy.
Outcome Measures: Quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness.
Results of Base-Case Analysis: Medical therapy yielded a median of 2.64 (interquartile range, 2.47 to 2.82) discounted QALYs and a median discounted lifetime cost of $34 400 (interquartile range, $31 100 to $37 700). Cardiac resynchronization therapy was associated with a median incremental cost of $107 800 (interquartile range, $79 800 to $156 500) per additional QALY.
Results of Sensitivity Analysis: Results were sensitive to changes in several variables, including the relative risk for death or hospitalization.
Limitations: These results apply to patients who meet the inclusion criteria of the currently completed trials.
Conclusions: The incremental cost per QALY for cardiac resynchronization is similar to that of other commonly used interventions but is sensitive to changes in several key variables. Resynchronization therapy should not be considered in patients with comorbid illness that shortens life expectancy.
Editors' Notes
Context
Contribution
Cautions
The Editors
Author and Article Information
From University of WashingtonHarborview Prehospital Emergency Care Research and Training Center and Harborview Medical Center, Seattle, Washington; Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada; University of Alberta, Edmonton, Alberta, Canada; and Case Western Reserve University, Cleveland, Ohio.
See related article: Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure by F.A. McAlister, J.A. Ezekowitz, N. Wiebe, B. Rowe, C. Spooner, E. Crumley, L. Hartling, T. Klassen, and W. Abraham.
See editorial: Cardiac Resynchronization for Heart Failure by M.A. Hlatky and B.M. Massie.
Disclaimer: The authors of this manuscript are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an endorsement by or an official position of the Agency for Healthcare Research and Quality, the U.S. Department of Health and Human Services, or the Heart and Stroke Foundation.
Acknowledgments: The authors thank Drs. David Atkins and Donald E. Casey Jr., who reviewed a draft of this work for the Agency for Healthcare Research and Quality, for their advice.
Grant Support: This research was conducted by the University of Alberta Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (contract no. 290-02-0023). Additional support was provided by the Heart and Stroke Foundation of Canada (grant no. NA4443).
Potential Financial Conflicts of Interest: Grants received: G. Nichol (Medtronic of Canada, Medtronic, Inc., Guidant Corp., Canadian Institutes of Health Research).
Requests for Single Reprints: Graham Nichol, MD, University of WashingtonHarborview Prehospital Emergency Care Research and Training Center, Harborview Medical Center, 325 Ninth Avenue, Box 359747, Seattle, WA 98104; e-mail, nichol{at}u.washington.edu.
Current Author Addresses: Dr. Nichol: University of WashingtonHarborview Prehospital Research and Training Center, Harborview Medical Center, 325 Ninth Avenue, Box 359747, Seattle, WA 98104.
Dr. Kaul: Department of Medicine, University of Alberta, 7221 Aberhart CenterI, 8440 112 Street, Edmonton, Alberta T6G 2B7, Canada.
Ms. Huszti: Ottawa Health Research Institute, 1053 Carling Avenue, Ottawa, Ontario K1Y 4E9, Canada.
Dr. Bridges: Department of Epidemiology and Biostatistics, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4945.
Author Contributions: Conception and design: G. Nichol.
Analysis and interpretation of the data: G. Nichol, E. Huszti, J.F.P. Bridges.
Drafting of the article: G. Nichol, J.F.P. Bridges.
Critical revision of the article for important intellectual content: E. Huszti.
Final approval of the article: G. Nichol, P. Kaul, E. Huszti.
Provision of study materials or patients: G. Nichol.
Statistical expertise: E. Huszti, J.F.P. Bridges.
Obtaining of funding: G. Nichol.
Administrative, technical, or logistic support: G. Nichol.
Collection and assembly of data: G. Nichol, P. Kaul, J.F.P. Bridges. ARTICLE
Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure
![]()
![]()
This article has been cited by other articles:
![]() |
J. J. Goldberger, M. E. Cain, S. H. Hohnloser, A. H. Kadish, B. P. Knight, M. S. Lauer, B. J. Maron, R. L. Page, R. S. Passman, D. Siscovick, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death: A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1179 - 1199. [Full Text] [PDF] |
||||
![]() |
J. J. Goldberger, M. E. Cain, S. H. Hohnloser, A. H. Kadish, B. P. Knight, M. S. Lauer, B. J. Maron, R. L. Page, R. S. Passman, D. Siscovick, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death: A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention Circulation, September 30, 2008; 118(14): 1497 - 1518. [Full Text] [PDF] |
||||
![]() |
F. A. McAlister, J. Ezekowitz, N. Hooton, B. Vandermeer, C. Spooner, D. M. Dryden, R. L. Page, M. A. Hlatky, and B. H. Rowe Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction: A Systematic Review JAMA, June 13, 2007; 297(22): 2502 - 2514. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Yao, N. Freemantle, M. J. Calvert, S. Bryan, J.-C. Daubert, and J. G.F. Cleland The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator Eur. Heart J., January 1, 2007; 28(1): 42 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Assomull, S. K. Prasad, J. Lyne, G. Smith, E. D. Burman, M. Khan, M. N. Sheppard, P. A. Poole-Wilson, and D. J. Pennell Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy J. Am. Coll. Cardiol., November 21, 2006; 48(10): 1977 - 1985. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Mueller, K. Laule-Kilian, C. Schindler, T. Klima, B. Frana, D. Rodriguez, A. Scholer, M. Christ, and A. P. Perruchoud Cost-effectiveness of B-Type Natriuretic Peptide Testing in Patients With Acute Dyspnea. Arch Intern Med, May 22, 2006; 166(10): 1081 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kearney, G. Stokoe, G. Breithardt, C. Longson, J. Marco, J. Morgan, S. Priori, A. Ruether, R. Taylor, M. Hertog, et al. Improving patient access to novel medical technologies in Europe Eur. Heart J., April 1, 2006; 27(7): 882 - 885. [Abstract] [Full Text] [PDF] |
||||
![]() |
O.-A. Breithardt and G. Breithardt Quest for the Best Candidate: How Much Imaging Do We Need Before Prescribing Cardiac Resynchronization Therapy? Circulation, February 21, 2006; 113(7): 926 - 928. [Full Text] [PDF] |
||||
![]() |
F. A. McAlister, J. V. Tu, A. Newman, D. S. Lee, S. Kimber, B. Cujec, and P. W. Armstrong How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts Eur. Heart J., February 1, 2006; 27(3): 323 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Leclercq, G. Ansalone, F. Gadler, G. Boriani, N. Perez-Castellano, N. Grubb, S. Sack, and E. Boulogne Biventricular vs. left univentricular pacing in heart failure: rationale, design, and endpoints of the B-LEFT HF study. Europace, January 1, 2006; 8(1): 76 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Feldman, G. de Lissovoy, M. R. Bristow, L. A. Saxon, T. De Marco, D. A. Kass, J. Boehmer, S. Singh, D. J. Whellan, P. Carson, et al. Cost Effectiveness of Cardiac Resynchronization Therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial J. Am. Coll. Cardiol., December 20, 2005; 46(12): 2311 - 2321. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2125 - 2133. [Full Text] [PDF] |
||||
![]() |
M. J. Calvert, N. Freemantle, G. Yao, J. G.F. Cleland, L. Billingham, J.-C. Daubert, S. Bryan, and on behalf of the CARE-HF Investigators Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial Eur. Heart J., December 2, 2005; 26(24): 2681 - 2688. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Berger The Ethics of Deactivating Implanted Cardioverter Defibrillators Ann Intern Med, April 19, 2005; 142(8): 631 - 634. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Jarcho Resynchronizing Ventricular Contraction in Heart Failure N. Engl. J. Med., April 14, 2005; 352(15): 1594 - 1597. [Full Text] [PDF] |
||||
![]() |
ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB Evid. Based Med., April 1, 2005; 10(2): 62 - 62. [Full Text] [PDF] |
||||
![]() |
Cost-Effectiveness of Cardiac Resynchronization Therapy Journal Watch Cardiology, October 22, 2004; 2004(1022): 3 - 3. [Full Text] |
||||
![]() |
Cardiac Resynchronization for Heart Failure: Effective but Costly Journal Watch (General), October 1, 2004; 2004(1001): 2 - 2. [Full Text] |
||||
![]() |
M. A. Hlatky and B. M. Massie Cardiac Resynchronization for Heart Failure Ann Intern Med, September 7, 2004; 141(5): 399 - 400. [Full Text] [PDF] |
||||
![]() |
F. A. McAlister, J. A. Ezekowitz, N. Wiebe, B. Rowe, C. Spooner, E. Crumley, L. Hartling, T. Klassen, and W. Abraham Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure Ann Intern Med, September 7, 2004; 141(5): 381 - 390. [Abstract] [Full Text] [PDF] |
||||